Financial Results
Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023.
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13), the innovative, commercial-stage biopharmaceutical company, today reports its unaudited financial results for the six months ended June 30, 2023 and provides updates on key clinical and commercial developments.
Akeso Inc. Published 2023 Interim Results Positive Profit Alert
Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced that it is expected that the Company will record a profit of not less than RMB2.3 billion for the six months ended June 30, 2023.
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023.
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology announces that, it is anticipated that the Company will record a significant increase in its revenue for the six months ended June 30, 2023.
Henlius Forecasts Profit in 1H 2023
Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months ended June 30, 2023, the company expects to turn into profits in the first half of 2023, achieving profitability for the first time in a six-month period.
HUTCHMED to Announce 2023 Half-Year Financial Results
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
Prenetics Announces First Quarter 2023 Financial Results
Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
BEIJING, May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023.
